Foundry Investment Discipline Industry-Neutral Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.11T | 24.14% |
2JNJ | JOHNSON & JOHNSON | Healthcare | $609.12B | 13.24% |
3ABBV | ABBVIE INC | Healthcare | $449.63B | 9.78% |
4MRK | MERCK & CO INC | Healthcare | $314.90B | 6.85% |
5AMGN | AMGEN INC | Healthcare | $197.69B | 4.30% |
6ABT | ABBOTT LABORATORIES | Healthcare | $175.37B | 3.81% |
7GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 3.62% |
8PFE | PFIZER INC | Healthcare | $142.77B | 3.10% |
9BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 2.70% |
10VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $123.26B | 2.68% |
11REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $70.94B | 1.54% |
12IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 0.97% |
13CBRE | CBRE GROUP INC | Real Estate | $41.28B | 0.90% |
14RVMD | REVOLUTION MEDICINES INC | Healthcare | $39.58B | 0.86% |
15TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $37.30B | 0.81% |
16ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 0.78% |
17ONC | BEONE MEDICINES LTD | Healthcare | $34.68B | 0.75% |
18RPRX | ROYALTY PHARMA PLC | Healthcare | $33.50B | 0.73% |
19ZTS | ZOETIS INC | Healthcare | $32.10B | 0.70% |
20BIIB | BIOGEN INC | Healthcare | $30.41B | 0.66% |
21ROIV | ROIVANT SCIENCES LTD | Healthcare | $24.82B | 0.54% |
22MRNA | MODERNA INC | Healthcare | $24.53B | 0.53% |
23INSM | INSMED INC | Healthcare | $23.48B | 0.51% |
24UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 0.49% |
25VTRS | VIATRIS INC | Healthcare | $20.14B | 0.44% |
26INVH | INVITATION HOMES INC | Real Estate | $17.89B | 0.39% |
27NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 0.37% |
28BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.94B | 0.35% |
29JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.53B | 0.34% |
30JLL | JONES LANG LASALLE INC | Real Estate | $15.34B | 0.33% |
31CDE | COEUR MINING INC | Basic Materials | $14.85B | 0.32% |
32ELAN | ELANCO ANIMAL HEALTH INC | Healthcare | $12.90B | 0.28% |
33MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $12.76B | 0.28% |
34AXSM | AXSOME THERAPEUTICS INC | Healthcare | $11.84B | 0.26% |
35BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $11.52B | 0.25% |
36TECH | BIO-TECHNE CORP | Healthcare | $11.29B | 0.25% |
37SMMT | SUMMIT THERAPEUTICS INC | Healthcare | $10.72B | 0.23% |
38ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $10.47B | 0.23% |
39KRYS | KRYSTAL BIOTECH INC | Healthcare | $10.46B | 0.23% |
40APGE | APOGEE THERAPEUTICS INC | Healthcare | $10.10B | 0.22% |
41CYTK | CYTOKINETICS INC | Healthcare | $9.98B | 0.22% |
42CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 0.21% |
43KYMR | KYMERA THERAPEUTICS INC | Healthcare | $9.52B | 0.21% |
44HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.20% |
45PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $9.06B | 0.20% |
46IONS | IONIS PHARMACEUTICALS INC | Healthcare | $8.99B | 0.20% |
47CRNX | CRINETICS PHARMACEUTICALS INC | Healthcare | $8.84B | 0.19% |
48ALKS | ALKERMES PLC | Healthcare | $8.79B | 0.19% |
49TGTX | TG THERAPEUTICS INC | Healthcare | $8.40B | 0.18% |
50RGEN | REPLIGEN CORP | Healthcare | $8.31B | 0.18% |
51IMVT | IMMUNOVANT INC | Healthcare | $8.27B | 0.18% |
52PCVX | VAXCYTE INC | Healthcare | $8.12B | 0.18% |
53IBRX | IMMUNITYBIO INC | Healthcare | $8.04B | 0.17% |
54TRNO | TERRENO REALTY CORP | Real Estate | $7.98B | 0.17% |
55MIRM | MIRUM PHARMACEUTICALS INC | Healthcare | $7.25B | 0.16% |
56LNTH | LANTHEUS HOLDINGS INC | Healthcare | $7.00B | 0.15% |
57RIOT | RIOT PLATFORMS INC | Financial Services | $6.91B | 0.15% |
58COGT | COGENT BIOSCIENCES INC | Healthcare | $6.68B | 0.15% |
59XENE | XENON PHARMACEUTICALS INC | Healthcare | $6.60B | 0.14% |
60PTCT | PTC THERAPEUTICS INC | Healthcare | $6.52B | 0.14% |
61CGON | CG ONCOLOGY INC | Healthcare | $6.34B | 0.14% |
62SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $6.33B | 0.14% |
63LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.08B | 0.13% |
64ERAS | ERASCA INC | Healthcare | $5.96B | 0.13% |
65TWST | TWIST BIOSCIENCE CORP | Healthcare | $5.84B | 0.13% |
66DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.77B | 0.13% |
67AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $5.69B | 0.12% |
68ORKA | ORUKA THERAPEUTICS INC | Healthcare | $5.59B | 0.12% |
69TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.11% |
70KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.11% |
71CRSP | CRISPR THERAPEUTICS AG | Healthcare | $4.61B | 0.10% |
72ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $4.38B | 0.10% |
73EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $4.28B | 0.09% |
74TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.13B | 0.09% |
75DYN | DYNE THERAPEUTICS INC | Healthcare | $3.92B | 0.09% |
76CPRX | CATALYST PHARMACEUTICALS INC | Healthcare | $3.85B | 0.08% |
77RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.81B | 0.08% |
78DNLI | DENALI THERAPEUTICS INC | Healthcare | $3.70B | 0.08% |
79ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | Healthcare | $3.67B | 0.08% |
80ALMS | ALUMIS INC | Healthcare | $3.65B | 0.08% |
81ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.56B | 0.08% |
82OGN | ORGANON & CO | Healthcare | $3.55B | 0.08% |
83JOE | ST JOE CO | Real Estate | $3.48B | 0.08% |
84GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $3.45B | 0.07% |
85RCUS | ARCUS BIOSCIENCES INC | Healthcare | $3.44B | 0.07% |
86VAC | MARRIOTT VACATIONS WORLDWIDE CORP | Consumer Cyclical | $3.43B | 0.07% |
87ELVN | ENLIVEN THERAPEUTICS INC | Healthcare | $3.24B | 0.07% |
88IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.16B | 0.07% |
89UE | URBAN EDGE PROPERTIES | Real Estate | $2.99B | 0.06% |
90IRON | DISC MEDICINE INC | Healthcare | $2.91B | 0.06% |
91RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $2.88B | 0.06% |
92BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.83B | 0.06% |
93SUPN | SUPERNUS PHARMACEUTICALS INC | Healthcare | $2.79B | 0.06% |
94CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.77B | 0.06% |
95NMRK | NEWMARK GROUP INC | Real Estate | $2.77B | 0.06% |
96VERA | VERA THERAPEUTICS INC | Healthcare | $2.76B | 0.06% |
97TRVI | TREVI THERAPEUTICS INC | Healthcare | $2.71B | 0.06% |
98KOD | KODIAK SCIENCES INC | Healthcare | $2.67B | 0.06% |
99ATAI | ATAIBECKLEY INC | Healthcare | $2.66B | 0.06% |
100TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $2.58B | 0.06% |
101QURE | UNIQURE NV | Healthcare | $2.54B | 0.06% |
102IMNM | IMMUNOME INC | Healthcare | $2.53B | 0.05% |
103NRIX | NURIX THERAPEUTICS INC | Healthcare | $2.40B | 0.05% |
104VCEL | VERICEL CORP | Healthcare | $2.38B | 0.05% |
105PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.36B | 0.05% |
106BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $2.36B | 0.05% |
107AGIO | AGIOS PHARMACEUTICALS INC | Healthcare | $2.36B | 0.05% |
108BHVN | BIOHAVEN LTD | Healthcare | $2.32B | 0.05% |
109NKTR | NEKTAR THERAPEUTICS | Healthcare | $2.31B | 0.05% |
110NEOG | NEOGEN CORP | Healthcare | $2.24B | 0.05% |
111MLYS | MINERALYS THERAPEUTICS INC | Healthcare | $2.23B | 0.05% |
112IOVA | IOVANCE BIOTHERAPEUTICS INC | Healthcare | $2.23B | 0.05% |
113GTY | GETTY REALTY CORP | Real Estate | $2.19B | 0.05% |
114GLUE | MONTE ROSA THERAPEUTICS INC | Healthcare | $2.07B | 0.05% |
115AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.05B | 0.04% |
116RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $2.04B | 0.04% |
117NUVB | NUVATION BIO INC | Healthcare | $2.03B | 0.04% |
118ADMA | ADMA BIOLOGICS INC | Healthcare | $2.02B | 0.04% |
119ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $1.97B | 0.04% |
120AMLX | AMYLYX PHARMACEUTICALS INC | Healthcare | $1.97B | 0.04% |
121OCUL | OCULAR THERAPEUTIX INC | Healthcare | $1.96B | 0.04% |
122URGN | UROGEN PHARMA LTD | Healthcare | $1.96B | 0.04% |
123HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.04% |
124TYRA | TYRA BIOSCIENCES INC | Healthcare | $1.91B | 0.04% |
125MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.04% |
126IIPR | INNOVATIVE INDUSTRIAL PROPERTIES INC | Real Estate | $1.86B | 0.04% |
127SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 0.04% |
128STOK | STOKE THERAPEUTICS INC | Healthcare | $1.81B | 0.04% |
129ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.80B | 0.04% |
130IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.78B | 0.04% |
131ZYME | ZYMEWORKS INC | Healthcare | $1.77B | 0.04% |
132HYMC | HYCROFT MINING HOLDING CORP | Basic Materials | $1.74B | 0.04% |
133HROW | HARROW INC | Healthcare | $1.74B | 0.04% |
134TSHA | TAYSHA GENE THERAPIES INC | Healthcare | $1.71B | 0.04% |
135ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.04% |
136INVA | INNOVIVA INC | Healthcare | $1.60B | 0.03% |
137VIR | VIR BIOTECHNOLOGY INC | Healthcare | $1.59B | 0.03% |
138NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 0.03% |
139FOR | FORESTAR GROUP INC | Real Estate | $1.53B | 0.03% |
140XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $1.52B | 0.03% |
141PRGO | PERRIGO CO PLC | Healthcare | $1.48B | 0.03% |
142MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.45B | 0.03% |
143PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.35B | 0.03% |
144NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.03% |
145STAA | STAAR SURGICAL CO | Healthcare | $1.32B | 0.03% |
146XNCR | XENCOR INC | Healthcare | $1.30B | 0.03% |
147ARDX | ARDELYX INC | Healthcare | $1.28B | 0.03% |
148INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.28B | 0.03% |
149CRVS | CORVUS PHARMACEUTICALS INC | Healthcare | $1.25B | 0.03% |
150PDM | PIEDMONT REALTY TRUST INC | Real Estate | $1.23B | 0.03% |
151QDEL | QUIDELORTHO CORP | Healthcare | $1.19B | 0.03% |
152COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $1.17B | 0.03% |
153ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.16B | 0.03% |
154MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $1.15B | 0.03% |
155SDGR | SCHRODINGER INC | Healthcare | $1.14B | 0.02% |
156SVRA | SAVARA INC | Healthcare | $1.13B | 0.02% |
157CAPR | CAPRICOR THERAPEUTICS INC | Healthcare | $1.13B | 0.02% |
158WVE | WAVE LIFE SCIENCES LTD | Healthcare | $1.12B | 0.02% |
159ORIC | ORIC PHARMACEUTICALS INC | Healthcare | $1.11B | 0.02% |
160PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.01B | 0.02% |
161OLMA | OLEMA PHARMACEUTICALS INC | Healthcare | $1.00B | 0.02% |
162FBRX | FORTE BIOSCIENCES INC | Healthcare | $1.00B | 0.02% |
163JANX | JANUX THERAPEUTICS INC | Healthcare | $992M | 0.02% |
164VOR | VOR BIOPHARMA INC | Healthcare | $980M | 0.02% |
165MUX | MCEWEN INC | Basic Materials | $978M | 0.02% |
166ANRO | ALTO NEUROSCIENCE INC | Healthcare | $967M | 0.02% |
167KURA | KURA ONCOLOGY INC | Healthcare | $964M | 0.02% |
168ANNX | ANNEXON INC | Healthcare | $950M | 0.02% |
169TBPH | THERAVANCE BIOPHARMA INC | Healthcare | $873M | 0.02% |
170PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $873M | 0.02% |
171AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $871M | 0.02% |
172REPL | REPLIMUNE GROUP INC | Healthcare | $859M | 0.02% |
173SLDB | SOLID BIOSCIENCES INC | Healthcare | $859M | 0.02% |
174HPP | HUDSON PACIFIC PROPERTIES INC | Real Estate | $853M | 0.02% |
175CYRX | CRYOPORT INC | Industrials | $832M | 0.02% |
176ACRS | ACLARIS THERAPEUTICS INC | Healthcare | $793M | 0.02% |
177DSGN | DESIGN THERAPEUTICS INC | Healthcare | $785M | 0.02% |
178FPH | FIVE POINT HOLDINGS LLC | Real Estate | $778M | 0.02% |
179CTO | CTO REALTY GROWTH INC | Real Estate | $751M | 0.02% |
180RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 0.02% |
181CADL | CANDEL THERAPEUTICS INC | Healthcare | $746M | 0.02% |
182AURA | AURA BIOSCIENCES INC | Healthcare | $723M | 0.02% |
183OMER | OMEROS CORP | Healthcare | $701M | 0.02% |
184SPRY | ARS PHARMACEUTICALS INC | Healthcare | $695M | 0.02% |
185CRMD | CORMEDIX INC | Healthcare | $661M | 0.01% |
186TECX | TECTONIC THERAPEUTIC INC | Healthcare | $615M | 0.01% |
187NGNE | NEUROGENE INC | Healthcare | $590M | 0.01% |
188GYRE | GYRE THERAPEUTICS INC | Healthcare | $587M | 0.01% |
189MYGN | MYRIAD GENETICS INC | Healthcare | $584M | 0.01% |
190STTK | SHATTUCK LABS INC | Healthcare | $577M | 0.01% |
191FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $575M | 0.01% |
192IMMX | IMMIX BIOPHARMA INC | Healthcare | $558M | 0.01% |
193CTNM | CONTINEUM THERAPEUTICS INC | Healthcare | $532M | 0.01% |
194VSTM | VERASTEM INC | Healthcare | $530M | 0.01% |
195ZURA | ZURA BIO LTD | Healthcare | $518M | 0.01% |
196ARVN | ARVINAS INC | Healthcare | $517M | 0.01% |
197DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $517M | 0.01% |
198RGNX | REGENXBIO INC | Healthcare | $511M | 0.01% |
199XOMA | XOMA ROYALTY CORP | Healthcare | $504M | 0.01% |
200TRC | TEJON RANCH CO | Industrials | $491M | 0.01% |
201FRPH | FRP HOLDINGS INC | Real Estate | $461M | 0.01% |
202PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.01% |
203KYTX | KYVERNA THERAPEUTICS INC | Healthcare | $453M | 0.01% |
204IDR | IDAHO STRATEGIC RESOURCES INC | Basic Materials | $449M | 0.01% |
205BNTC | BENITEC BIOPHARMA INC | Healthcare | $439M | 0.01% |
206PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.01% |
207BOC | BOSTON OMAHA CORP | Communication Services | $430M | 0.01% |
208ASMB | ASSEMBLY BIOSCIENCES INC | Healthcare | $426M | 0.01% |
209CBIO | CRESCENT BIOPHARMA INC | Healthcare | $407M | 0.01% |
210USNA | USANA HEALTH SCIENCES INC | Consumer Defensive | $403M | 0.01% |
211ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $400M | 0.01% |
212ABEO | ABEONA THERAPEUTICS INC | Healthcare | $399M | 0.01% |
213EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.01% |
214DMAC | DIAMEDICA THERAPEUTICS INC | Healthcare | $393M | 0.01% |
215STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.01% |
216EOLS | EVOLUS INC | Healthcare | $377M | 0.01% |
217ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.01% |
218NATR | NATURES SUNSHINE PRODUCTS INC | Consumer Defensive | $359M | 0.01% |
219VNDA | VANDA PHARMACEUTICALS INC | Healthcare | $327M | 0.01% |
220LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $311M | 0.01% |
221FHTX | FOGHORN THERAPEUTICS INC | Healthcare | $305M | 0.01% |
222TKNO | ALPHA TEKNOVA INC | Healthcare | $291M | 0.01% |
223TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $268M | 0.01% |
224ARL | AMERICAN REALTY INVESTORS INC | Real Estate | $257M | 0.01% |
225QTTB | Q32 BIO INC | Healthcare | $255M | 0.01% |
226SRZN | SURROZEN INC | Healthcare | $255M | 0.01% |
227RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $243M | 0.01% |
228ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.01% |
229KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.00% |
230KROS | KEROS THERAPEUTICS INC | Healthcare | $211M | 0.00% |
231AGEN | AGENUS INC | Healthcare | $209M | 0.00% |
232IMUX | IMMUNIC INC | Healthcare | $207M | 0.00% |
233DTIL | PRECISION BIOSCIENCES INC | Healthcare | $203M | 0.00% |
234ACOG | ALPHA COGNITION INC | Healthcare | $185M | 0.00% |
235OZ | BELPOINTE PREP LLC | Real Estate | $181M | 0.00% |
236INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.00% |
237KRRO | KORRO BIO INC | Healthcare | $177M | 0.00% |
238ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.00% |
239STRS | STRATUS PROPERTIES INC | Real Estate | $165M | 0.00% |
240LENZ | LENZ THERAPEUTICS INC | Healthcare | $162M | 0.00% |
241RCEL | AVITA MEDICAL INC | Healthcare | $157M | 0.00% |
242UNCY | UNICYCIVE THERAPEUTICS INC | Healthcare | $144M | 0.00% |
243CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.00% |
244STHO | STAR HOLDINGS | Real Estate | $114M | 0.00% |
245USGO | US GOLDMINING INC | Basic Materials | $109M | 0.00% |
246FTLF | FITLIFE BRANDS INC | Consumer Defensive | $104M | 0.00% |
247CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $103M | 0.00% |
248ICCC | IMMUCELL CORP | Healthcare | $101M | 0.00% |
249VRCA | VERRICA PHARMACEUTICALS INC | Healthcare | $96M | 0.00% |
250CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.00% |
251INTG | INTERGROUP CORP | Consumer Cyclical | $84M | 0.00% |
252LFVN | LIFEVANTAGE CORP | Consumer Defensive | $78M | 0.00% |
253ACET | ADICET BIO INC | Healthcare | $76M | 0.00% |
254ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.00% |
255CLNN | CLENE INC | Healthcare | $76M | 0.00% |
256LONA | LEONABIO INC | Healthcare | $68M | 0.00% |
257IMA | IMAGENEBIO INC | Healthcare | $61M | 0.00% |
258XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.00% |
259APT | ALPHA PRO TECH LTD | Basic Materials | $53M | 0.00% |
260MCRB | SERES THERAPEUTICS INC | Healthcare | $52M | 0.00% |
261EXOZ | EXOZYMES INC | Healthcare | $51M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $4.60T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 97% toward Large, 73% toward Growth. +2% unclassified (33 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 261 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual66.0%Margin-9.0%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual24.1%Margin0.9%Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.
The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).
Required<= 25.0%Actual97.3%Margin-72.3%Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActualunboundedMargin—
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 261 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 16%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 25.1% | 20.7% |
| 3 yearsp.a. | 12.5% | -7.0% |
| 5 yearsp.a. | 4.3% | -7.5% |
| 10 yearsp.a. | 8.4% | -4.6% |
| Since inceptionp.a. | 8.0% | 1.9% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | -1.5% | -7.2% |
| 2025 | 50.7% | 29.6% |
| 2024 | -5.0% | -35.4% |
| 2023 | -2.0% | -14.0% |
| 2022 | -8.4% | 8.0% |
| 2021 | 20.1% | 4.2% |
| 2020 | 18.2% | 6.5% |
| 2019 | 31.2% | 0.7% |
| 2018 | -15.6% | -10.1% |
| 2017 | 18.0% | -4.3% |
| 2016 | -2.1% | -12.3% |
| 2015 | 2.0% | 15.8% |
| 2014 | 16.0% | 8.2% |
| 2013 | 33.3% | -7.0% |
| 2012 | 12.2% | -11.2% |
| 2011 | -3.6% | -6.5% |
| 2010 | 12.1% | -2.7% |
| 2009 | 26.4% | 2.0% |
| 2008 | -31.7% | 37.1% |
| 2007 | -8.1% | -12.4% |
| 2006 | 14.1% | -2.0% |
| 2005 | 10.2% | 4.1% |
| 2004 | 2.6% | -6.0% |
| 2003 | 36.7% | -1.5% |
| 2002 | -26.2% | 4.5% |
| 2001 | 0.8% | 45.4% |
| 2000 | 24.8% | 58.7% |
| 1999 | 45.8% | 5.0% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Investment Discipline Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a Investment Discipline signal and holds the top decile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.